Sangamo Therapeutics to Regain Full Rights to Hemophilia A …
Dec 31, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & …
Tagrisso approved in the EU for patients with unresectable EGFR …
Dec 23, 2024 · Approval based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years In the trial, Tagrisso reduced the …
Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial ...
Dec 20, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & …
Expression Therapeutics Announces Promising Phase 1 Results for ...
ATLANTA, GA, USA I December 11, 2024 I Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy — ET3 — for …
Sumitomo Pharma America Announces U.S. FDA Approval of …
Dec 23, 2024 · – GEMTESA ® is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH – . …
BlueRock Therapeutics advances investigational cell therapy ...
Jan 13, 2025 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & …
Vertex Announces Results From Phase 2 Study of Suzetrigine for …
Dec 20, 2024 · “Suzetrigine has again demonstrated its potential to fill an important unmet need in the treatment of pain. Today’s LSR results are consistent with previous studies of this pain …
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A …
Dec 17, 2024 · – Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular …
Tessera Therapeutics Receives Investment to Develop Curative In …
Dec 20, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & …
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as …
Dec 21, 2024 · BRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients …